Sintx Technologies, Inc. (NASDAQ: SINT)

Sintx Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. The company specializes in silicon nitride (Si₃N₄), a material known for its biocompatibility, bioactive properties, and resistance to bacterial adhesion. Sintx Technologies operates primarily in the medical device industry, focusing on musculoskeletal and antipathogenic applications. The company's products have been implanted in humans since 2008, demonstrating their clinical efficacy and safety.

Sintx Technologies generates revenue through the manufacture and sale of products, including coatings, materials, and components for aerospace and medical device markets. The company also derives revenue from toll processing services and government contracts and grants. Key products include the SiNAPTIC® Foot & Ankle Osteotomy Wedge System, which received FDA 510(k) clearance in October 2025, enabling the company's commercial entry into reconstructive foot and ankle surgery in the United States. Additionally, Sintx Technologies offers OsseoSculpt®, a next-generation biologic designed to complement the foot and ankle osteotomy wedges. The company's customer base includes medical device manufacturers, healthcare providers, and government agencies.

• Biomedical Applications: Sintx Technologies focuses on medical-grade silicon nitride products that are biocompatible, bioactive, and antipathogenic. The company's portfolio includes spinal implants, foot and ankle osteotomy wedges, and other orthopedic devices. The SiNAPTIC® Foot & Ankle Osteotomy Wedge System is a notable product in this segment, catering to the reconstructive foot and ankle surgery market. The company also develops products for arthroplasty implants, foot wedges, and dental implants, leveraging the unique properties of silicon nitride.

• Antipathogenic Applications: Sintx Technologies incorporates its unique composition of silicon nitride antipathogenic powder into products such as face masks, drapes, filters, sutures, and wound care devices. This segment aims to manufacture surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. The discovery that Sintx silicon nitride inactivates SARS-CoV-2 has opened new markets and applications for the material.

Sintx Technologies holds a strong position in the advanced ceramics industry, particularly in the medical device sector. The company's competitive advantages include its expertise in silicon nitride manufacturing, a material with superior properties such as bone affinity, resistance to bacterial and viral infection, ease of diagnostic imaging, resistance to corrosion, and superior strength and fracture resistance. These advantages are validated by a large and growing inventory of peer-reviewed, published literature reports. The company's strategic focus on proprietary silicon nitride-based biomedical devices offers stronger margins, a more defensible competitive position, and better long-term value for shareholders. Key competitors include other medical device manufacturers and advanced ceramics companies, but Sintx Technologies differentiates itself through its innovative use of silicon nitride in medical applications.

The company's general customer base includes medical device manufacturers, healthcare providers, and government agencies. Sintx Technologies' products are primarily sold in the United States, with a growing focus on international markets. The company's strategic repositioning away from non-core, low-margin OEM technical manufacturing contracts is aimed at improving long-term profitability and sustainability. Sintx Technologies continues to invest in the development and regulatory advancement of silicon nitride-based orthopedic and surgical implants, positioning itself as a leading provider in the medical device market.